German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT). The treatment is intended for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Drug Profile
Nubeqa is an oral androgen receptor inhibitor (ARi). It has previously received FDA approvals for use in combination with docetaxel for adults with mHSPC and as a monotherapy for adults with non-metastatic castration-resistant prostate cancer (nmCRPC).
Significance
This positive opinion from the CHMP underscores the potential of darolutamide plus ADT as a treatment option for mHSPC patients. It reflects the drug’s established efficacy and safety profile in prostate cancer therapy.-Fineline Info & Tech
